Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Современный взгляд на патогенез и принципы лечения предменструального синдрома
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлены современные данные об этиологии и патогенезе, факторах риска предменструального синдрома, основные принципы диагностики и лечения этого патологического состояния.
Ключевые слова: предменструальный синдром, лечение предменструального синдрома.
Ключевые слова: предменструальный синдром, лечение предменструального синдрома.
________________________________________________
The article presents the current data on etiology, pathogenesis, risk factors of premenstrual syndrome, and the basic principles of diagnosis and treatment of this pathological condition.
Key words: premenstrual syndrome, the treatment of premenstrual syndrome.
Полный текст
Список литературы
1. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health 2010; 13 (6): 485–94.
2. Baker LJ, O’Brien PM. Premenstrual syndrome (PMS): a peri-menopausal perspective. Maturitas 2012; 72 (2): 121–5.
3. Birzniece V, Bäckström T, Johansson IM et al. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res Rev 20064 51 (2): 212–39. Epub 2005 Dec 20.
4. Matsumoto T, Asakura H, Hayashi T. Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder. Gynecol Endocrinol 2013; 29 (1): 67–73.
5. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71 (12): 1565–75.
6. Poiană C, Muşat M, Carsote M, Chiriţă C. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi 2009; 113 (4): 996–1000.
7. Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause Int 2011; 17 (3): 96–101.
8. Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. Timing of alcohol use and the incidence of premenstrual syndrome and probable premenstrual dysphoric disorder. J Womens Health 2009; 18 (12): 1945–53.
9. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология. СПб.: СОТИС, 1995. Т. I; с. 129–38.
10. Кузнецова М.Н. Клиника, патогенез и лечение предменструального синдрома. Дис. ... д-ра мед наук. М., 1971.
11. Mathew PG, Dun EC, Luo JJ. A cyclic pain: the pathophysiology and treatment of menstrual migraine. Obstet Gynecol Surv 2013; 68 (2): 130–40.
12. Allais G, Gabellari IC, Burzio C et al. Premenstrual syndrome and migraine. Neurol Sci 2012; 33 (Suppl. 1): S111–5.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
14. McLaren JS, Morris E, Rymer J. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update. Menopause Int 2012; 18 (2): 68–72.
15. Freeman EW et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 2012; 85 (5): 437–45.
16. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2.
17. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011; 32 (1): 42–51.
18. Freeman EW. Therapeutic management of premenstrual syndrome. Expert Opin Pharmacother 2010; 11 (17): 2879–89.
2. Baker LJ, O’Brien PM. Premenstrual syndrome (PMS): a peri-menopausal perspective. Maturitas 2012; 72 (2): 121–5.
3. Birzniece V, Bäckström T, Johansson IM et al. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res Rev 20064 51 (2): 212–39. Epub 2005 Dec 20.
4. Matsumoto T, Asakura H, Hayashi T. Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder. Gynecol Endocrinol 2013; 29 (1): 67–73.
5. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71 (12): 1565–75.
6. Poiană C, Muşat M, Carsote M, Chiriţă C. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi 2009; 113 (4): 996–1000.
7. Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause Int 2011; 17 (3): 96–101.
8. Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. Timing of alcohol use and the incidence of premenstrual syndrome and probable premenstrual dysphoric disorder. J Womens Health 2009; 18 (12): 1945–53.
9. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология. СПб.: СОТИС, 1995. Т. I; с. 129–38.
10. Кузнецова М.Н. Клиника, патогенез и лечение предменструального синдрома. Дис. ... д-ра мед наук. М., 1971.
11. Mathew PG, Dun EC, Luo JJ. A cyclic pain: the pathophysiology and treatment of menstrual migraine. Obstet Gynecol Surv 2013; 68 (2): 130–40.
12. Allais G, Gabellari IC, Burzio C et al. Premenstrual syndrome and migraine. Neurol Sci 2012; 33 (Suppl. 1): S111–5.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
14. McLaren JS, Morris E, Rymer J. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update. Menopause Int 2012; 18 (2): 68–72.
15. Freeman EW et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 2012; 85 (5): 437–45.
16. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2.
17. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011; 32 (1): 42–51.
18. Freeman EW. Therapeutic management of premenstrual syndrome. Expert Opin Pharmacother 2010; 11 (17): 2879–89.
________________________________________________
1. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health 2010; 13 (6): 485–94.
2. Baker LJ, O’Brien PM. Premenstrual syndrome (PMS): a peri-menopausal perspective. Maturitas 2012; 72 (2): 121–5.
3. Birzniece V, Bäckström T, Johansson IM et al. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res Rev 20064 51 (2): 212–39. Epub 2005 Dec 20.
4. Matsumoto T, Asakura H, Hayashi T. Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder. Gynecol Endocrinol 2013; 29 (1): 67–73.
5. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71 (12): 1565–75.
6. Poiană C, Muşat M, Carsote M, Chiriţă C. Premenstrual dysphoric disorder: neuroendocrine interferences. Rev Med Chir Soc Med Nat Iasi 2009; 113 (4): 996–1000.
7. Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. Menopause Int 2011; 17 (3): 96–101.
8. Bertone-Johnson ER, Hankinson SE, Johnson SR, Manson JE. Timing of alcohol use and the incidence of premenstrual syndrome and probable premenstrual dysphoric disorder. J Womens Health 2009; 18 (12): 1945–53.
9. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология. СПб.: СОТИС, 1995. Т. I; с. 129–38.
10. Кузнецова М.Н. Клиника, патогенез и лечение предменструального синдрома. Дис. ... д-ра мед наук. М., 1971.
11. Mathew PG, Dun EC, Luo JJ. A cyclic pain: the pathophysiology and treatment of menstrual migraine. Obstet Gynecol Surv 2013; 68 (2): 130–40.
12. Allais G, Gabellari IC, Burzio C et al. Premenstrual syndrome and migraine. Neurol Sci 2012; 33 (Suppl. 1): S111–5.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007; 23 (3): 123–30.
14. McLaren JS, Morris E, Rymer J. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update. Menopause Int 2012; 18 (2): 68–72.
15. Freeman EW et al. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception 2012; 85 (5): 437–45.
16. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2.
17. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol 2011; 32 (1): 42–51.
18. Freeman EW. Therapeutic management of premenstrual syndrome. Expert Opin Pharmacother 2010; 11 (17): 2879–89.
Авторы
В.Е.Балан, Л.М.Ильина
ГБУЗ МО Московский областной научно-исследовательский институт акушерства и гинекологии
ГБУЗ МО Московский областной научно-исследовательский институт акушерства и гинекологии
________________________________________________
V.E.Balan, L.M.Ilyina
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.